Your browser doesn't support javascript.
loading
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein.
Behrens, Anna-Janina; Vasiljevic, Snezana; Pritchard, Laura K; Harvey, David J; Andev, Rajinder S; Krumm, Stefanie A; Struwe, Weston B; Cupo, Albert; Kumar, Abhinav; Zitzmann, Nicole; Seabright, Gemma E; Kramer, Holger B; Spencer, Daniel I R; Royle, Louise; Lee, Jeong Hyun; Klasse, Per J; Burton, Dennis R; Wilson, Ian A; Ward, Andrew B; Sanders, Rogier W; Moore, John P; Doores, Katie J; Crispin, Max.
Afiliação
  • Behrens AJ; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Vasiljevic S; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Pritchard LK; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Harvey DJ; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Andev RS; Department of Infectious Diseases, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London SE1 9RT, UK.
  • Krumm SA; Department of Infectious Diseases, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London SE1 9RT, UK.
  • Struwe WB; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Cupo A; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10021, USA.
  • Kumar A; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Zitzmann N; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Seabright GE; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
  • Kramer HB; Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK.
  • Spencer DI; Ludger, Ltd., Culham Science Centre, Abingdon, Oxfordshire OX14 3EB, UK.
  • Royle L; Ludger, Ltd., Culham Science Centre, Abingdon, Oxfordshire OX14 3EB, UK.
  • Lee JH; Department of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and CAVD, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Klasse PJ; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10021, USA.
  • Burton DR; Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center and CAVD, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, the Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technolog
  • Wilson IA; Department of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and CAVD, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical B
  • Ward AB; Department of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and CAVD, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Sanders RW; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10021, USA; Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, 1105 AZ Amsterdam,
  • Moore JP; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10021, USA.
  • Doores KJ; Department of Infectious Diseases, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London SE1 9RT, UK. Electronic address: katie.doores@kcl.ac.uk.
  • Crispin M; Oxford Glycobiology Institute and Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK. Electronic address: max.crispin@bioch.ox.ac.uk.
Cell Rep ; 14(11): 2695-706, 2016 Mar 22.
Article em En | MEDLINE | ID: mdl-26972002
ABSTRACT
The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it from immune surveillance. The high density of glycans on the trimer surface imposes steric constraints limiting the actions of glycan-processing enzymes, so that multiple under-processed structures remain on specific areas. These oligomannose glycans are recognized by broadly neutralizing antibodies (bNAbs) that are not thwarted by the glycan shield but, paradoxically, target it. Our site-specific glycosylation analysis of a soluble, recombinant trimer (BG505 SOSIP.664) maps the extremes of simplicity and diversity of glycan processing at individual sites and reveals a mosaic of dense clusters of oligomannose glycans on the outer domain. Although individual sites usually minimally affect the global integrity of the glycan shield, we identify examples of how deleting some glycans can subtly influence neutralization by bNAbs that bind at distant sites. The network of bNAb-targeted glycans should be preserved on vaccine antigens.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polissacarídeos / Proteína gp120 do Envelope de HIV / HIV-1 Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polissacarídeos / Proteína gp120 do Envelope de HIV / HIV-1 Idioma: En Ano de publicação: 2016 Tipo de documento: Article